

State of Alabama Opioid Settlements
Amounts Received/Expected
Current as of May 8, 2025

I. McKinsey

- A. The State received its final payment of \$394,879.85 in April 2025.
- B. The ultimate total received by the State, after attorneys' fees, was **\$7,285,822.62**.

II. McKesson

- A. The total abatement amount is \$141 million, to be paid over ten years, split evenly between the State and local entities (subdivisions, county health departments, and public hospitals).
- B. The State has received payments for Years 1 through 3 totaling \$21,150,000.
- C. McKesson will pay the State \$7,050,000 per year, with \$50,000 subtracted from the final year's payment if the one municipality that did not participate does not file suit against McKesson (McKesson was not obligated to pay any amount because the State did not have full participation, but it agreed to do so in exchange for the \$50,000 holdback from the final payment).
- D. The ultimate total for the State will be **\$70,450,000**.

III. Janssen (J&J)

- A. The total abatement amount was \$70,329,014.38, split evenly between the State and local entities.
- B. The ultimate total received by the State was **\$24,949,880.12**.

IV. Cardinal Health & Cencora (formerly AmerisourceBergen)

- A. The total abatement amount is \$220 million, to be paid over ten years. The settlement is being split evenly between the State and local entities.
- B. The State has received payment for Year 1 totaling \$11 million (\$5,491,200 from Cardinal and \$5,508,800 from Cencora).
- C. The ultimate total for the State will be **\$110 million**.

V. Walmart

- A. The total abatement payment amount was \$38,700,000, with most going to the local entities. The ultimate total received by the State was **\$3,000,000**.

VI. Publicis

- A. The State received **\$5,473,818.20**.

VII. Allergan

- A. Alabama's share (state and local) is **\$34,040,657.07**, to be paid over seven years. The settlement is being split evenly between the State and local entities.
- B. The State's ultimate share after splitting with the local entities will be ~\$17,020,328.54.
- C. The State has received its shares of the first two payments, which totaled **\$4,944,961.99**.

VIII. Teva

- A. Alabama's share (state and local) is **~\$57,138,933.98**, to be paid over 13 years. The settlement is being split evenly between the State and local entities.
- B. The State's ultimate share after splitting with the local entities will be ~\$28,569,466.99.

C. There is also a product option which we could convert to cash. As it stands now, the cash value of the product is set at \$240,000,000. The State's share of the cash conversion would come to \$4,655,647.13.

D. The State has received its shares of the first two payments, which totaled **\$4,675,151.64**.

IX. CVS

A. Alabama's share is **~\$75,851,591.91**, to be paid over 10 years. The settlement is being split evenly between the State and local entities. abatement amount is \$4,279,160,837, over 10 years.

B. The State's ultimate share will be **~\$37,790,795.96**.

C. The State has received its shares first two payments, which totaled **\$4,933,573.10**.

X. Walgreens

A. Alabama's share is **~\$82,187,066.19**, to be paid over 10 years. The settlement is being split evenly between the State and local entities.

B. The State's ultimate share after splitting with the local entities will be **~\$41,093,533.10**.

C. The State has received its Year 3 payment. The State's share of that payment was \$2,132,962.34. To date, the State has received a total of **\$4,779,508.58**.

D. The first two payments to the State totaled \$2,646,546.24. The amount was reduced by \$2,657,115.83, as those funds were included in the payment to the local entities in exchange for the local entities' return of the same amount of Mallinckrodt funds (see below).

XI. Mallinckrodt Bankruptcy

A. Alabama has received a total of **\$5,314,234.66** (two separate payments of \$2,441,674.01 and \$2,872,557.65).

- B. As the recipient of the Mallinckrodt funds, the Attorney General must submit a report to the Trust identifying the abatement purposes on which Mallinckrodt funds have been spent. This report must identify spending by the State any other entity that receives Mallinckrodt funds from the Office of the Attorney General.
- C. In order to lessen the burden the reporting requirements place on local entities, the State has agreed to take back the local share of the Mallinckrodt funds and provide the local entities with an equivalent share from other settlements. The total amount paid back to the State from the local entities' Mallinckrodt funds is \$2,657,115.83. The State paid the equivalent share out of its first payment from the Walgreens settlement.
- D. The State has received \$176,124.12 in attorneys' fees from the National Opioid Abatement Trust II State Fee Fund.

XII. Endo Bankruptcy

- A. Alabama has received a total of **\$5,027,225.65** from the Endo bankruptcy. The State has also received \$ 219,832.22 to cover costs.
- B. Like the Mallinckrodt bankruptcy plan, the Endo bankruptcy plan imposes reporting requirements on each entity that receives funds. In order to minimize the burden those requirements place on the local entities, the State has agreed with the local entities that the State will retain the local share of Endo funds and provide the local entities with an equivalent share of funds from other settlement payments (exclusive of costs).

Future Settlements

XIII. Kroger

- A. Alabama's share is ~\$20,500,000, to be paid over six years. The settlement is being split evenly between the State and local entities.
- B. The State has obtained full participation from all required local entities to receive full payment, and Kroger has agreed to go forward with the settlement. The first payment should come in 2025.

XIV. Purdue Bankruptcy

- A. The Supreme Court has reversed the Second Circuit's approval of the bankruptcy plan, holding that the Sacklers cannot obtain releases through the bankruptcy. As a result, the original settlement agreement between the states and Purdue, which included contributions from the Sacklers in exchange for the releases, has been affected.